XML 28 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Revenue and Cost of Revenue
 6 Months Ended
Jun. 30, 2024
Revenue Recognition and Deferred Revenue [Abstract]  
Revenue and Cost of Revenue

13. Revenue and cost of revenue

 

There was no revenue earned, or cost of revenue recognized in the three and six months ended June 30, 2024.

 

In the three and six months ended June 2023, the Company recognized milestone proceeds of $9.0 million as revenue under the license and collaboration agreement with Ultragenyx for setrusumab following achievement of a development milestone. As a

consequence of this milestone received, and in accordance with the terms of the 2015 asset purchase agreement with Novartis which requires payment of a percentage of the proceeds received, subject to certain deductions, the Company also recognized cost of revenue of $3.4 million for the three months ended June 30, 2023 and $3.1 million for the six months ended June 30, 2023.